China NMPA Drug Inspection - Hubei Minkang Pharmaceutical Co., Ltd. - sandalwood

The Hubei Province Drug Quality Announcement, published on October 31, 2019, details the findings from drug quality sampling inspections conducted during the third quarter of 2018. These inspections, carried out by Hubei food and drug administration departments, identified 107 batches of non-compliant drugs from numerous pharmaceutical manufacturers, pharmacies, and healthcare facilities across the province. Key violations encompassed critical quality specification issues, including improper pH values, excessive moisture content, unacceptable impurity levels, inconsistent content uniformity, poor dissolution rates, and exceeding microbial limits. These deficiencies were found in finished pharmaceutical preparations, traditional Chinese medicinal materials, and hospital-prepared medications. A significant finding included several counterfeit drugs, such as Atorvastatin Calcium Tablets, where identified manufacturers explicitly denied their production. Additionally, some samples were found to have been stored at temperatures exceeding specified conditions. The regulatory framework for these actions includes the "Drug Administration Law of the People's Republic of China," the Chinese Pharmacopoeia, and other national and provincial drug standards. Affected entities are required to investigate these issues, implement corrective measures, and report findings to the Provincial Bureau. Suspected criminal activity, particularly involving unverified manufacturers or unclear drug sourcing, mandates prompt referral to public security authorities for prosecution, underscoring the commitment to drug safety.